Chirurgisches Management des renalen
                    Hyperparathyreoidismus

K. Lorenz; C. Sekulla; H. Dralle

doi:10.1055/s-0030-1262542

Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie, Inhaltsverzeichnis

Zentralbl Chir 2013; 138(S 02): e47-e54
DOI: 10.1055/s-0030-1262542

Übersicht

Georg Thieme Verlag KG Stuttgart · New York

Chirurgisches Management des renalen Hyperparathyreoidismus

Surgical Management of Renal Hyperparathyroidism

K. Lorenz

Martin-Luther Universität Halle-Wittenberg, Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Halle / Saale, Deutschland

,

C. Sekulla

Martin-Luther Universität Halle-Wittenberg, Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Halle / Saale, Deutschland

,

H. Dralle

Martin-Luther Universität Halle-Wittenberg, Klinik für Allgemein-, Viszeral- und Gefäßchirurgie, Halle / Saale, Deutschland

› Institutsangaben

Abstract

Zusammenfassung

Das konservative Konzept zur Therapie des renalen Hyperparathyreoidismus hat sich durch neue Medikamente, insbesondere durch die Kalzimimetika gewandelt. In der Folge wurde vielfach über einen Rückgang der Operationsfrequenz bei renalem Hyperparathyreoidismus berichtet. Vor diesem Hintergrund müssen die Rolle der chirurgischen Therapie, die chirurgische Strategie und das operative Verfahren für diese Indikationsstellung neu bestimmt werden. Anhand einer Literaturübersicht wird eine aktuelle Standortbestimmung des chirurgischen Therapiekonzeptes beim renalen Hyperparathyreoidismus vorgenommen und Einflüsse der neuen medikamentösen Therapien aufgezeigt. Die verschiedenen Operationsverfahren werden beschrieben und nach den aktuellen Indikationskriterien eingeordnet. Zusammenfassend zeigen sich der Zeitpunkt und die Indikationsstellung für chirurgische Maßnahmen durch die Kalzimimetika beeinflusst, die Operation der Nebenschilddrüsen bleibt jedoch weiterhin die einzige dauerhaft wirksame Therapie des renalen Hyperparathyreoidismus.

Abstract

Conservative management of renal hyperparathyroidism has changed recently. Innovative substances, especially the advent of calcimimetics, have influenced the therapeutic concept. Consequently, a decline in surgical frequency for renal hyperparathyroidism has been reported. In this context it is now mandatory to evaluate the role of surgery, the surgical strategy and procedures for renal hyperparathyroidism anew. Based on a review of the literature the current position of surgical indications and care for renal hyperparathyroidism as well as possible influences of innovative medical treatment are highlighted. In summary, the timing and indications for surgery have been influenced, however, surgery still remains the only permanently effective treatment option for renal hyperparathyroidism.

Schlüsselwörter

endokrine Chirurgie - renaler Hyperparathyreoidismus - Kalzimimetika

Key words

endocrine surgery - renal hyperparathyroidism - calcimimetics

Volltext

Referenzen

Literatur
Reichel H, Drüke T, Ritz E. Skeletal disorders. In: Davison AM, Cameron JS, Gruenfeld JP, Kerr DN, Ritz E, Winearls CG, Hrsg. Oxford textbook of clinical nephrology. Vol. 111. Oxford, New York, Tokio: Oxford University Press; 1998: 1954-1981
Ganesh SK, Stack AG, Lewin NW et al. Association of elevated serum PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001; 12: 2131-2138
Kestenbaum B, Sampson JN, Rudser KD et al. Serum phoshate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528
Fukuda N, Tanaka H, Tominaga Y et al. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-1443
Gogusev J, Duchambon P, Hory B et al. Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism. Kidney Int 1997; 51: 328-336
Ritz E, Seidel A. Pathogenese des sekundären Hyperparathyreoidismus bei Niereninsuffizienz. In: Schulz A, Hümpfner A, Hrsg Knochen, kalziumregulierende Hormone und Niere. Dustri; München: 1992: 56-64
Ritz E, Szabo A, Reichel H. Parathyroidectomy in secondary (renal) hyperparathyroidism – whom, when, how?. Int J Artif Organs 1993; 16: 7-10
Rothmund M Hrsg Hyperparathyreoidismus. Thieme; Stuttgart: 1991
Rothmund M, Wagner PK, Schark C. Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: A randomized trial. World J Surg 1991; 15: 745-750
National Kidney Foundation. K / DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: 1-201
KDIGO. Clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009; 113: 1-130
Locatelli F, Limardo M, Pontoriero G. New approaches to treatment of secondary hyperparathyroidism. Curr Opin Inv Drugs 2008; 9: 363-370
Cohen EP, Moulder JE. Parathyroidectomy in chronic renal failure: Has medical care reduced the need for surgery?. Nephron 2001; 89: 271-273
Cunningham J. Are parathyroidectomies still appropriate in chronic dialysis patients?. Semin Dial 2000; 5: 275-278
Shahapuni I, Monge M, Oprisiu R et al. Drug insight: Renal indications of calcimimetics. Nat Clin Pract Nephrol 2006; 6: 316-325
Nemeth EF, Heaton WH, Miller M et al. Pharmacodynamics of the type II calcimimetic compound cinacalect HCl. J Pharmacol Exp Ther 2004; 308: 627-635
Mimpara® / Sensipar® (cinacalcet HCl). Full prescribing information. Amgen Inc.. Thousand Oaks, California, USA: 2007
Padhi D, Harris RZ, Salfi M et al. No effect of renal function or dialysis on pharmakinetics of cinacalcet (Sensipar / Mimpara). Clin Pharmakinet 2005; 44: 509-516
Block GA, Martin KJ, De Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-1525
Lindberg JS, Culleron B, Wong G et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: A randomized, double-blind, multicentric study. J Am Soc Nephrol 2005; 16: 800-807
Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800
Wüthrich RP, Martin D, Bilezikian JP. The role of calcimimetics in the treatment of hyperparathyroidism. Eur J Clin Invest 2007; 37: 915-922
Young EW, Akiba T, Albert JM et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Am J Kidney Dis 2004; 44: 34-38
Block GA, Klassen P, Danese M. Association between proposed NKF-K / DOQI bone metabolism and disease guidelines and mortality risk in hemodialysis patients. J Am Soc Nephrol 2003; 14: 474-474
Perez Garcia R, Garcia F, Martin-Malo A et al. Progression of bone mineral metabolism parameters in the first year after hemodialysis (HD) initiation in Spain: ANSWER study. J Am Soc Nephrol 2006; 17: 135-135
Onada N, Kashiwagi T, Nakamura T et al. Parathyroid interventions for secondary hyperparathyroidism in hemodialyzed patients. Ther Apher Dial 2005; 9: 11-15
Yumita S. Intervention for recurrent secondary hyperparathyroidism from a residual gland. Nephrol Dial Transplant 2003; 18: 62-64
Tominaga Y, Numano M, Tanaka Y et al. Surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 1997; 13: 87-96
Lorenz K, Dralle H. Chirurgie des Hyperparathyroidismus. Chirurg 2003; 74: 593-616
Tominaga Y, Matsuoka S, Sato T. Surgical indications and procedures of parathyroidectomy in patients with chronic kidney disease. Ther Apher Dial 2005; 9: 44-47
Elder GJ. Parathyreoidectomy in the calcimimetic era. Nephrology 2005; 10: 511-515
Moka D, Voth E, Dietlein M et al. Technetium 99m-MIBI-SPECT: A highly sensitive diagnostic tool for localization of parathyroid adenomas. Surgery 2000; 128: 29-35
Chen H, Civelek C, Westra WH et al. Use of technetium Tc^99m sestamibi scintigraphy for recurrent tertiary hyperparathyroidism from a parathyroid forearm graft. South Med J 2000; 93: 215-217
Spanu A, Migaleddu V, Manca A et al. The usefulness of single photone emission computerized tomography with pinhole collimator (P-SPECT) in preoperative localization of hyperfunctioning parathyroid glands in patients with secondary hyperparathyroidism. Radiol Med 2003; 106: 399-412
Lorenz K, Ukkat J, Sekulla C et al. Total parathyroidectomy without autotransplantation for renal hyperparathyroidism: Experience with a qPTH-controlled protocol. World J Surg 2006; 30: 743-751
Hampl H, Steinmüller T, Fröhling P et al. Long-term results of total parathyroidectomy without autotransplantation in patients with and without renal failure. Miner Electrolyte Metab 1999; 25: 161-170
Akerström G, Malmeus J, Bergström R. Surgical anatomy of human parathyroid glands. Surgery 1984; 95: 14-21
Gagner M, Inabnet WB. Endoscopic subtotal parathyroidectomy in patients with primary hyperparathyroidism. Br J Surg 1996; 83: 875-875
Ikeda Y, Takami H, Tajima G et al. Total endoscopic parathyroidectomy. Biomed Pharmacother 2002; 56: 22-25
Barbaros U, Erbil Y, Yildrim A et al. Minimally invasive video-assisted subtotal parathyroidectomy with thymectomy for secondary hyperparathyroidism. Langenbecks Arch Surg 2009; 394: 451-455
Barreto FC, Barreto DV, Moyses RM et al. K / DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73: 771-777
Müller-Stich BP, Brändle M, Binet I et al. To autotransplant simultaneously or not-can intraoperative parathyroid hormone monitoring reliably predict early postoperative parathyroid hormone levels after total parathyroidectomy for hyperplasia?. Surgery 2007; 142: 47-56
Ikeda Y, Kurihara H, Morita N et al. The role of bio-intact PTH (1–84) assay during parathyroidectomy for secondary hyperparathyroidism. J Surg Res 2007; 141: 306-310
Bieglmayer C, Kaczirek K, Prager C et al. Parathyroid hormone monitoring during total parathyroidectomy for renal hyperparathyroidism: Pilot study of the impact of renal function and assay specificity. Clin Chem 2006; 52: 1112-1119
Yamashita H, Cantor T, Uchino S et al. Sequential changes in plasma intact and whole parathyroid hormone levels during parathyroidectomy for secondary hyperparathyroidism. World J Surg 2005; 29: 169-173
Koonsmann M, Hughes K, Dickerman R et al. Parathyroidectomy in chronic renal failure. Am J Surg 1994; 168: 631-634
Willeke F, Richter A, Schnelle P. Subtotal parathyroidectomy in the treatment of secondary hyperparathyroidism. Langenbecks Arch Surg 1996; 387: 204-209
Gasparri G, Camandona M, Abbona GC et al. Secondary and tertiary hyperparathyroidism: Causes of recurrent disease after 446 parathyroidectomies. Ann Surg 2001; 233: 656-659
Seehofer D, Rayes N, Ulrich F et al. Intraoperative measurement of intact parathyroid hormone in renal hyperparathyroidism by an inexpensive routine assay. Langenbecks Arch Surg 2001; 386: 440-443
Dotzenrath C, Cupisti K, Goretzki PE et al. Operative treatment of renal autonomous hyperparathyroidism: Cause of persistent or recurrent disease in 304 patients. Langenbecks Arch Surg 2003; 387: 348-354
Triponez F, Dosseh D, Hazzan M et al. Subtotal parathyroidectomy with thymectomy for autonomous hyperparathyroidism after renal transplantation. Br J Surg 2005; 92: 1282-1287
Takagi H, Tominaga Y, Tanaka Y et al. Total parathyroidectomy with forearm autograft for secondary hyperparathyroidism in chronic renal failure. Ann Surg 1996; 206: 639-644
Schmid T, Müller P, Spelsberg F. Parathyroidectomy after renal transplantation: A retrospective analysis of long-term outcome. Nephrol Dial Transplant 1997; 12: 2393-2396
Walgenbach S, Hommel G, Bernhard G et al. Prospektive Beobachtungsstudie zur operativen Therapie des renalen Hyperparathyreoidismus. Chirurg 1997; 68: 147-153
Tominaga Y, Uchida H, Haba T et al. More than 1 000 cases of total parathyroidectomy with forearm autograft for renal hyperparathyroidism. Am J Kidney Dis 2001; 38: 168-171
Neyer U, Hörandner H, Haid A et al. Total parathyroidectomy with autotransplantation in renal hyperparathyroidism: Low recurrence after intra-operative tissue collection. Nephrol Dial Transplant 2002; 17: 625-629
Stracke S, Jehle PM, Sturm D et al. Clinical course after total parathyroidectomy without autotransplantation in patients with end-stage renal failure. Am J Kidney Dis 1999; 33: 304-311
Ockert S, Willeke F, Richter A et al. Total parathyroidectomy without autotransplantation as a standard procedure in the treatment of secondary hyperparathyroidism. Langenbecks Arch Surg 2002; 387: 204-209
Saunders RN, Karoo R, Metcalfe MS et al. Four gland parathyroidectomy without reimplantation in patients with chronic renal failure. Postgrad Med J 2005; 81: 255-258
Felsenfeld AJ, Harrelson JM, Gutman RA et al. Osteomalacia after parathyroidectomy in patients with uremia. Ann Intern Med 1982; 96: 34-39
Drezner MK, Neelon FA, Jowsey J et al. Hypoparathyroidism: A possible cause of osteomalacia. J Clin Endocrinol Metab 1977; 45: 114-122
Matsuoka S, Tominaga Y, Sato T et al. Recurrent renal hyperparathyroidism caused by parathyromatosis. World J Surg 2007; 31: 299-305
Casanova D, Sarfati E, De Francisco A et al. Secondary hyperparathyroidism: Diagnosis of site recurrence. World J Surg 1991; 15: 546-549
Kilgo MS, Pirsch JD, Warner TF et al. Tertiary hyperparathyroidism after renal transplantation: Surgical strategy. Surgery 1998; 124: 677-684
Kerby JD, Loring LW, Blair H et al. Operative treatment of tertiary hyperparathyroidism. A single center experience. Ann Surg 1998; 227: 878-886
Schlosser K, Endres N, Celik I et al. Surgical treatment of tertiary hyperparathyroidism: The choice of procedure matters!. World J Surg 2007; 31: 1947-1953
Triponez F, Clark OH, Vanrenthergem Y et al. Surgical treatment of persistent hyperparathyroidism after renal transplantation. Ann Surg 2008; 248: 18-30
Dralle H. Operative treatment of renal autonomous hyperparathyroidism: Causes for persistent or recurrent disease in 304 patients. Langenbecks Arch Surg 2003; 387: 392-394 Comments on C. Dotzenrath et al.